OncoMatch/Clinical Trials/NCT07502287

Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

Is NCT07502287 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including EB-DTNB-NK and Fludarabine for relapsed neuroblastoma.

Phase 1/2RecruitingBeijing BiotechNCT07502287Data as of May 2026

Treatment: EB-DTNB-NK · Fludarabine · Cyclophosphamide — This illustrative Phase 1/Phase 2 study tests allogeneic dual-target GD2/B7-H3 (CD276) CAR-NK cells in children and young adults with relapsed or refractory neuroblastoma. After lymphodepletion, participants receive IV CAR-NK cells;Part A defines the RP2D and Part B estimates preliminary activity

Check if I qualify

Extracted eligibility criteria

Cancer type

Neuroblastoma

Biomarker criteria

Required: GD2 expression (positive)

Tumor material available for central assessment of GD2 and B7-H3 expression; at least one target must be positive

Required: CD276 expression (positive)

Tumor material available for central assessment of GD2 and B7-H3 expression; at least one target must be positive

Prior therapy

Must have received: standard neuroblastoma therapy

Prior exposure to standard neuroblastoma therapy, including anti-GD2-based therapy, unless contraindicated, unavailable, or declined for a documented medical reason

Cannot have received: genetically modified cellular therapy

Prior genetically modified cellular therapy within the protocol-defined washout window

Lab requirements

Blood counts

adequate hematologic function considered sufficient by protocol-defined laboratory and clinical thresholds

Kidney function

adequate renal function considered sufficient by protocol-defined laboratory and clinical thresholds

Liver function

adequate hepatic function considered sufficient by protocol-defined laboratory and clinical thresholds

Cardiac function

adequate cardiac function considered sufficient by protocol-defined laboratory and clinical thresholds

Adequate organ function: hematologic, renal, hepatic, cardiac, and pulmonary function considered sufficient by protocol-defined laboratory and clinical thresholds

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify